GSK plc 6-K, filed Jun 10, 2022
GSK plc (GSK)
6-K
2022-06-10
For: 2022-06-10
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on June 10, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 10 June 2022, London UK - LSE Announcement
GSK announces positive pivotal phase III data for its respiratory
syncytial virus (RSV) vaccine candidate for older
adults
●
First
RSV vaccine candidate to show statistically significant and
clinically meaningful efficacy in adults aged 60 years and
above
●
The magnitude of
effect observed was consistent across RSV A and B strains, key
secondary endpoints and in those aged 70 years and
above
●
Engagement with
regulators to start immediately with anticipated regulatory
submissions in H2 2022
GSK plc
(LSE/NYSE: GSK) today announced positive headline results from a
pre-specified efficacy interim analysis of the AReSVi 006 phase III
trial. The interim analysis was reviewed by an Independent Data
Monitoring Committee, and the primary endpoint was exceeded with no
unexpected safety concerns observed. AReSVi 006 is a phase III
trial investigating GSK's respiratory syncytial virus (RSV) vaccine
candidate for adults aged 60 years and above.
Dr Hal Barron, Chief Scientific Officer and President, R&D,
GSK, said: "These data suggest our
RSV vaccine
candidate offers exceptional protection for
older adults from the serious consequences of RSV infection. RSV
remains one of the few major infectious diseases without a vaccine,
and these data have the potential to meaningfully impact the
treatment of RSV and may reduce the 360,000 hospitalisations and
more than 24,000 deaths worldwide each year. Given the importance
of these data, we plan to engage with regulators immediately and
anticipate regulatory submissions in the second half of
2022."
Results
from this phase III trial will be presented in a peer-reviewed
publication and at an upcoming scientific meeting. The AReSVi 006
trial will continue to evaluate both an annual revaccination
schedule and longer-term protection over multiple seasons following
one dose of the RSV older adult (OA) vaccine
candidate.
GSK's
RSV OA vaccine candidate contains a recombinant subunit prefusion
RSV F glycoprotein antigen (RSVPreF3) combined with GSK's
proprietary AS01 adjuvant. AS01 is used with several of GSK's
established adjuvanted vaccines. The antigen plus adjuvant
combination may help overcome the natural age-related decline in
immunity that contributes to the challenge of protecting older
adults from RSV disease.
About AReSVi 006
The
AReSVi 006 phase III trial is a randomised, placebo-controlled,
observer-blind, multi-country trial to demonstrate the efficacy of
a single dose of GSK's adjuvanted RSVPreF3 OA investigational
vaccine in adults aged 60 years and above. Approximately 25,000
participants were enrolled from 17 countries.
AReSVi
006 is part of a comprehensive RSV evidence generation programme
conducted by GSK. Recent in-house results from a parallel phase III
trial, AReSVi 004, investigating the immunogenicity, safety,
reactogenicity, and persistence of the vaccine candidate in older
adults showed that, in participants aged 60 years and above, one
dose of the RSV OA investigational vaccine induced strong humoral
and cellular immune responses, which remain above pre-vaccination
levels up to at least the six months post-vaccination readout
timepoint.
AReSVi
006 is closely monitored for safety, with safety data reviewed
internally and by an external Independent Data Monitoring Committee
on an ongoing basis.
About respiratory syncytial virus (RSV)
RSV is a common contagious virus affecting the lungs and breathing
passages. It is one of the major remaining infectious diseases for
which there is currently no vaccine or specific treatment. Older
adults are at high risk for severe disease due to age-related
decline in immunity and underlying conditions. RSV can exacerbate
conditions including chronic obstructive pulmonary disease (COPD),
asthma and chronic heart failure and can lead to severe outcomes,
such as pneumonia, hospitalisation, and death. Each year, RSV
causes over 360,000 hospitalisations and 24,000 deaths globally in
adults. Adults with underlying conditions are more likely to seek
medical advice and have higher hospitalisation rates than adults
without these conditions.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in GSK's Annual
Report on Form 20-F for 2021 and any impacts of the COVID-19
pandemic.
This
announcement contains inside information. The person responsible
for arranging the release of this announcement on behalf of GSK is
Victoria Whyte, Company Secretary.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
10, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|